ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial
ASCEND：一项随机、双盲、安慰剂对照的II期临床研究，旨在评估吉西他滨联合白蛋白紫杉醇和LSTA1抑制剂治疗未经治疗的转移性胰腺腺癌的疗效。该研究由澳大利亚胃肠道试验组（AGITG）开展。
期刊:
影响因子:
doi:10.1016/j.esmogo.2023.07.001
Lee, J; Dean, A; Price, T; Sjoquist, K; Gebski, V; Mumford, J; Day, F; Yip, S; Wilson, K; Jackson, C; Padinharakam, S; Lee, B; Burge, M; Siu, D; Karapetis, C; Chantrill, L; Wong, Z W; Jennens, R; Lomma, C; Franscesconi, A; Ackland, S; Lynam, J; Wahlroos, S; So, J; Jameson, M; Tebbutt, N; Gill, S; Grimes, D; Steer, C; Harris, M
